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Background: The comorbidity of pain and depression is associated with high disease burden for patients in terms
of disability, wellbeing, and use of medical care. Patients with major and minor depression often present
themselves with pain to a general practitioner and recognition of depression in such cases is low, but evolving.
Also, physical symptoms, including pain, in major depressive disorder, predict a poorer response to treatment. A
multi-faceted, patient-tailored treatment programme, like collaborative care, is promising. However, treatment of
chronic pain conditions in depressive patients has, so far, received limited attention in research. Cost effectiveness
of an integrated approach of pain in depressed patients has not been studied.
This article describes the aims and design of a study to evaluate effects and costs of collaborative care with the
antidepressant duloxetine for patients with pain symptoms and a depressive disorder, compared to collaborative
care with placebo and compared to duloxetine alone.
(Continued on next page)* Correspondence: eheer@trimbos.nl
1Netherlands Institute of Mental Health and Addiction (Trimbos-institute),
Utrecht, The Netherlands
2Tilburg School of Behavioral and Social Sciences, Tranzo Department,
University of Tilburg, Tilburg, The Netherlands
Full list of author information is available at the end of the article
© 2013 de Heer et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
de Heer et al. BMC Psychiatry 2013, 13:147 Page 2 of 14
http://www.biomedcentral.com/1471-244X/13/147(Continued from previous page)
Methods/Design: This study is a placebo controlled double blind, three armed randomized multi centre trial.
Patients with (sub)chronic pain and a depressive disorder are randomized to either a) collaborative care with
duloxetine, b) collaborative care with placebo or c) duloxetine alone. 189 completers are needed to attain sufficient
power to show a clinically significant effect of 0.6 SD on the primary outcome measures (PHQ-9 score). Data on
depression, anxiety, mental and physical health, medication adherence, medication tolerability, quality of life,
patient-doctor relationship, coping, health resource use and productivity will be collected at baseline and after
three, six, nine and twelve months.
In the collaborative care conditions a) and b), a care-manager provides Problem Solving Treatment and integrated
symptom management guidance with a self-help manual, monitors depressive and pain symptoms, and refers
patients to a physiotherapist for treatment according to a 'Graded Activity' protocol. A psychiatrist provides
duloxetine or placebo and pain medication according to algorithms, and also monitors pain and depressive
symptoms. In condition c), the psychiatrist prescribes duloxetine without collaborative care. After 12 weeks, the
patient is referred back to the general practitioner with a consultation letter, with information for further treatment
of the patient.
Discussion: This study enables us to show the value of a closely monitored integrated treatment model above
usual pharmacological treatment. Furthermore, a comparison with a placebo arm enables us to evaluate
effectiveness of duloxetine in this population in a real life setting. Also, this study will provide evidence-based
treatments and tools for their implementation in practice. This will facilitate generalization and implementation of
results of this study. Moreover, patients included in this study are screened for pain symptoms, differentiating
between nociceptive and neuropathic pain. Therefore, pain relief can be thoroughly evaluated.
Trial registration: NTR1089
Keywords: Depression, Pain, Duloxetine, Collaborative Care, Transmural, Primary CareBackground
Patients with major depressive disorder (MDD) and co-
morbid chronic pain now have a high risk of not recei-
ving optimal care [1-4]. The burden of co-morbid pain
to depression is high for patients in terms of disability,
wellbeing, and use of medical care [5]. Complex, inte-
grated collaborative care including active pain mana-
gement is perhaps better for this population than
antidepressants alone, but there is limited evidence. Once
such integrated care is available and effective, the added
value of an antidepressant over placebo is also under
debate. In this trial we aim to evaluate to what extent
depressive symptoms improve in patients with MDD with
concomitant pain symptoms of both 6–12 weeks and ≥
12 weeks duration [6]: a) with collaborative care versus an
antidepressant alone, and b) with an antidepressant versus
placebo within the collaborative care condition.
There is a strong correlation between pain and psy-
chiatric distress reporting [7-11]. Physical symptoms,
including several pain symptoms, increase the likelihood
of a depressive disorder [12]. Also, many patients with
pain symptoms experience a depression [5,13,14], and
when the number of pain symptoms increases, the
prevalence of depression increases as well [15,16]. Vice
versa, when the severity of depression increases, so does
the severity of pain complaints [10]. Furthermore,
several studies indicate that pain symptoms are commonin patients with MDD: the ARTIST trial reports a 69%
rate of pain symptoms in primary care patients with
depression [17]; in psychiatric clinics in Spain, almost
60% of patients with depression had pain complaints
[18]; an international telephone survey in 18,980 patients
with MDD showed that 43.4% presented themselves with
chronic painful physical conditions [19], with headache,
back pain, and limb pain being the most prevalent; the
mean prevalence of pain was 65% in a meta analysis of
14 studies [5], and a US telephone survey reported a
65.6% prevalence of chronic pain in depressed persons
(N = 5808) [20]. Although a strong correlation has been
found between depression and pain, it is not clear if
depression causes pain [8], but it is suggested that pain
could be a symptom of depression [5,9,21]
Moreover, depression and painful physical symptoms
increase costs by increased utilization of healthcare
services [5,22-24]. A 2.8 and 4 fold expenditure elevation
is reported in depressed patients with back pain and
migraine, respectively [25]. These costs are the so-called
direct medical costs. But most costs of mental disorders in
general, and depression specifically, are indirect costs, as a
consequence of productivity loss and absenteeism: More
than 70% of the total costs of depression consists of these
indirect costs [26].
Therefore, good detection and diagnosis of comorbid
conditions is necessary in the first place to be able to
de Heer et al. BMC Psychiatry 2013, 13:147 Page 3 of 14
http://www.biomedcentral.com/1471-244X/13/147treat those conditions adequately [9,27]. In patients for
whom psychiatric consultation was asked by a General
Practitioner because of Medically Unexplained Symp-
toms including pain, up to 86% unrecognized depressive
and anxiety disorders were found by the consulting
psychiatrist [28,29]. Depression is high on the list of
possible diagnoses if a patient presents with multiple
unexplained physical symptoms including general aches
and pains [5,30]. However, even in case of recognition,
simple treatment of the depression is not sufficient.
Physical symptoms including pain in MDD are asso-
ciated with treatment resistance and predict a poorer
response to treatment [1-4,31]. Greater risk of relapse,
suicide, and substance abuse have been reported [32,33].
Residual symptoms in MDD predict relapse; patients
with residual symptoms relapsed 3 times as fast com-
pared to those who were asymptomatic at remission
[34]. Among patients with residual symptoms, > 90%
had mild-to-moderate physical symptoms including pain
[32]. Improvement in painful physical symptoms is
associated with higher remission rates in MDD [35]. In a
study in newly referred neurologic outpatients, pain
occurred in 10-55% of several diagnostic groups; and
comorbid MDD occurred in 10-30%. Pain as well as
MDD symptoms persisted over a period of 12 months,
and the authors stated that for remission of both,
interventions were needed specifically addressing pain
symptoms as well as depressive symptoms [36].
Treatment of chronic pain in depressed patients has
been addressed [33], with a focus on pain treatment.
Particularly for patients with both depression and pain,
flexible, integrated, multi-faceted [37], patient-tailored
methods of treatment are needed, in combination with
improvement of adherence, i.e. disease-management
programs such as collaborative care (CC) [38-40]. Two
recent meta-analyses have indeed shown the effective-
ness of such collaborative care approaches in primary
care [41,42]. Little is also known about the added effect
of an antidepressant such as duloxetine over placebo
when collaborative care is available.
Collaborative care is successful in the treatment of
depression, can vary in content and intensity [42] and
combines various interventions for the treatment of
disorders and includes active monitoring of symptoms,
through the use of questionnaires that are used at each
session with a professional. The contents of collaborative
care consist of a diagnostic assessment of complaints,
and contracting, to improve adherence. Also, a self-help
manual, guided by a care-manager, can be part of colla-
borative care. This manual contains information about
different symptoms and how to cope with them; the
coping can be addressed in terms of emotional coping,
cognitive coping and behavioral coping (e.g. tips for a
healthy lifestyle which can decrease physical complaints;information on pleasurable activities which can be done
with complaints) [43-46]. Next to this manual, a psycho-
therapy is offered in CC. Mostly, this is cognitive beha-
vioral therapy or problem solving treatment (PST), both
effective in the treatment of depression [47]. Next to
psychotherapy, medication can be an element of a
collaborative care approach, guided by a psychiatrist.
Several studies indicate that tricyclic antidepressants
(TCAs) are effective in the treatment if pain and depres-
sion coexist, as well as selective serotonin and noradre-
nalin reuptake inhibitors (SNRIs) such as duloxetine [48]
and venlafaxine, that have been shown to alleviate pain
and depressive symptoms [49-52]. However, in a meta-
analyses of Spielmans (2008) the analgesic effect of
Duloxetine has been questioned [53], which calls for
establishing the effect size for concomitant pain in
depressed patients by duloxetine. In case of comorbid
physical complaints, a physiotherapist can also be part
of a collaborative care approach. Because treatment in
CC is dependent on the process of symptom reduction,
systematic monitoring of the complaints is an important
part of CC. Furthermore, as a systematic review showed
that psychiatric consultation to primary care with a
consultation letter is effective for somatoform disorders
[54], adding the use of such a consultation letter to CC
can be useful. General practitioners (GP's) see treatment
of complex comorbid conditions such as the comorbid
condition under study as challenging and tend to refer
these patients to either mental health care or pain
specialists. Because GP's in general find treatment of this
patient group difficult, the benefits of a collaborative
care approach may be substantial and a transmural col-
laborative care approach may be useful [38-42].
Recently, a trial explored efficacy of collaborative care
for MDD and musculoskeletal pain [55] and another
trial explored efficacy of collaborative care for chronic
pain in the primary care setting [23], both with positive
results, but in one study the collaborative intervention
was more expensive than care as usual [56]. However,
treatment of other chronic pain conditions in depressive
patients has, so far, not received much attention. Also,
cost effectiveness of an integrated approach of pain in
depressed patients has not been studied yet.
Definition of (sub)chronic pain in this trial, and the way
its treatment is addressed in the collaborative care arm
According to the international Association for the study
of Pain (IASP), pain is an unpleasant sensory and
emotional experience associated with actual or potential
tissue damage, or described in terms of such damage [57].
Most pain originate from an outside stimulus (heat or
a sting), but may also result from injury to sensory fibres
(or even from damage to the central nervous system
itself ), and follows an ascending pathway to the brain
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the peripheral nervous system to the dorsal horn in the
spinal cord, and from there to the brain, where the
perception of pain is constructed. The dorsal horn acts
as a pathway for transmission of nociceptive information
[58-60]. In the brain, the descending control systems are
activated (possibly through the spinomesencephalic
tract). Serotonin (5-HT) appears to play an important
role in the descending pathway of pain [60].
Serotonin, norepinephrine, substance p, glutamate,
NMDA and gamma-aminobutyric acid (GABA) play a
role in pain processing in rats and mice [61-65] and in
humans [46,66]. Increasing the availability of norepi-
nephrine and 5-HT may promote pain inhibition centrally
[62]. At the central level, pain can be modulated by
attention [67] and by mood [68]. In chronic pain the
relationship between trigger and pain is not clear anymore
(or detected tissue damage cannot fully account for pain
intensity) and the pain persists past the normal time of
healing. Also, in chronic pain, gray matter degeneration
occurs in the anterior cingulated cortex and prefrontal cor-
tex as well as in the left parahippocampal cortex [69], brain
areas that are also implicated in depressive disorder and
that may diminish the ability of patients to learn [70,71],
and thus to follow treatment properly. Furthermore,
chronic pain is associated with sleep disturbances [72] and
chronic stress causes dendritic regression and loss of den-
dritic spines in hippocampal neurons that is accompanied
by deficits in synaptic plasticity and memory [73].
In this study, in the collaborative care treatment,
specific attention is paid to the management of pain by
proper pain medication and adherence to pain medica-
tion. For this purpose, the pain is classified as noci-
ceptive pain or neuropathic pain by a questionnaire, the
PAINDETECT [74] and treatment of pain will be
applied based on which of these two sorts of pain a pa-
tient has. Nociception leads to pain, but the amount of
pain experienced depends on integration in the cerebral
rostral centers, the dorsal horn, and in the peripheral
input. Neuropathic pain occurs without a damaging sti-
mulus of outside and is associated with increased excitation
and decreased inhibition of ascending pain pathways. Noci-
ceptive pain may have a protective nature, at least in its
acute form, but neuropathic pain is the result of nervous
damage [75]. However, in case of chronic pain, fibre loss
occurs in the spinal cord and in the peripheral nerve, due
to chronic central inhibition [63,76-78]. In some cases, the
pain can be mixed. An algorithm is used for administration
of pain medication according to the classification.
Confusion exists in terminology in describing physical
symptoms and pain associated with depression: They
may be somatised symptoms of MDD, or so-called asso-
ciated symptoms; Medically Unexplained Symptoms,
that frequently occur together with MDD; Chronicpainful physical conditions that are symptoms of a
chronic illness, such as diabetic neuropathy; or chronic
painful conditions resulting from centralisation of a
formerly peripheral pain symptom.
In this trial, we aim to improve depressive symptoms
of patients with MDD with concomitant subchronic or
chronic pain symptoms of nociceptive, neuropathic,
mixed or functional nature. As discerning nociceptive
pain from neuropathic pain may have therapeutic conse-
quences in the treatment of (sub)chronic pain [74], we
address both these issues in this RCT. We define
subchronic pain as pain with 6–12 weeks duration, and
chronic pain as pain of ≥ 12 weeks duration.
This Randomized Controlled Trial aims to evaluate
effectiveness and cost effectiveness of this transmural col-
laborative care model with Consultation Letter (TCCCL)
in patients with MDD and concomitant (sub)chronic
pain.
Methods/Design
Objectives
The primary objective of this randomized placebo-
controlled trial is to establish effectiveness on severity of
depression (measured by Patient Health Questionnaire
(PHQ-9)) of a closely monitored integrated intervention
(TCCCL + duloxetine) for concomitant depression and
(sub)chronic pain compared to either TCCCL + placebo
and compared to Duloxetine alone.
Secondary objectives of this trial are to establish cost
effectiveness in terms of Quality of Adjusted Life Years
(QALY) as measured by EuroQol-5 and SF-36 and costs
measured by TIC-P; and to establish improvement on
pain in terms of Brief Pain inventory (BPI).
The study will evaluate the following hypothesis
Hypothesis
Combined treatment (TCCCL +Duloxetine) is more
effective than mono-treatment (either TCCCL + placebo
or Duloxetine alone) in depressive symptom reduction
on the PHQ-9 as main outcome for patients with MDD
and (sub) chronic pain.
Study design
This study is a three armed randomized Multi Centre
trial led by GGz Breburg, with three collaborating
mental health institutions: GGz Breburg, Arkin, and
GGz inGeest, who will all include 73 patients in order to
have 3 × 63 completers for the study. See Figure 1 for
treatment options.
Participating mental health institutions
Three mental health institutions participate in this study.
Patients will be treated at these institutions according to
protocol. The participating mental health institutions are:
Figure 1 Treatment options.
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Arkin/PuntP, also in Amsterdam.Recruitment of care-managers and psychiatrists in the
Mental Health Institutions
Care-managers and psychiatrists will be recruited at the
three participating mental health centers (GGz Breburg,
Arkin, GGz inGeest) and form treatment teams for the
trial. The care-managers are psychiatric nurses or psy-
chologists who receive training in care management
(including PST) to provide in the collaborative care in-
terventions. The psychiatrists are trained in prescribing
duloxetine and placebo medications as well as the pain
medication according to the algorithm and in writing a
consultation letter for the general practitioner and pa-
tient. Psychiatrists are blinded for the antidepressant
medication (duloxetine/placebo), but not for the pain
medication. Pain medication management will be pro-
vided by the psychiatrists in the duloxetine and placebo
arm with collaborative care, but not in the treatment
arm with duloxetine alone. In this study, care-managers
and psychiatrists work according to a 'Case Registration
Form' (CRF). In this CRF all the steps are described that
a care-manager/psychiatrist has to do during an appoint-
ment with a patient.Recruitment of patients
All the patients that are referred to the participating
mental health centers are screened for depressive
symptoms and pain complaints. This study will focus on
patients with a depressive disorder and (sub)chronic
pain complaints. Sub chronic pain is defined as pain
of ≥ 6 weeks and chronic pain is defined as pain with a
duration of at least 12 weeks. Consecutive patients that
present themselves at the special mental health out-
patient clinic will be screened for MDD and concomi-
tant pain of ≥ 6 weeks duration with a questionnaire.This questionnaire will consist of the PHQ-9 [13] and
the item on 'average pain' from the BPI [79], that will be
used as a screener for respectively depressive disorder
and (sub)chronic pain symptoms. Also, the patient will
receive an informed consent form with information
about the study. Patients are eligible for the study if they
have a score of 10 or more on the PHQ-9 and a score of
3 or more on the 'average pain' item of the BPI. When a
patient screens positive on the questionnaires mentioned
above, the patient will receive a telephonic interview in
which a MINI interview will be administered in order to
clinically confirm the diagnosis MDD and to confirm
that the patient suffers from (sub)chronic pain. In that
case, he or she will receive additional information about
the treatment part of the study and will be asked if he or
she is willing to participate. When the patient is willing
to participate, the patient is included in the study. A
baseline questionnaire with second informed consent
form, for the treatment part of the study, will be sent to
the patient’s home address or made available on a se-
cured website. After completion of the baseline ques-
tionnaire, the patient will be randomized in one of the
three interventions.
Treatment allocation and blinding
This is a placebo controlled double blind study for the
medication part of the study, which means that the
allocation of duloxetine/placebo in the collaborative care
arm is blinded.
Patients visiting the three participating Mental Health
Institutions will be randomly assigned to one of the three
treatment groups. Collaborative care and Duloxetine alone
will be administered in a non-blind fashion. Administra-
tion of medication within the collaborative care conditions
will be double blind and placebo controlled. Outcome
assessments will be performed by a blinded research
assistant.
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After 12 weeks, the placebo-controlled part of the study
will end and the patient and physician will be deblinded
for this part of the intervention. This deblinding proce-
dure is described more detailed in the intervention.
Emergency deblinding
Emergency deblinding of the medication condition is
performed by telephone to a research associate who is
not involved in treatment procedures. This happens in
case of serious adverse medical events. Subjects, who are
deblinded before the end of the treatment procedures,
will not be incorporated in the final analysis. In case of
emergency deblinding or non-compliance, the code of
medication (duloxetine or placebo) in the collaborative
care groups will be broken. In case of duloxetine, the
medication will be reduced and stopped according to
protocol. All the remaining medication of this patient
will be asked back and stored in a closed cabinet, sepa-
rately from the rest of the study medication. In case of
non-compliance, the patient will be excluded from this
study and the final analysis.
Patient exclusion criteria
Patients with pain for which by diagnostic medical
assessment a structural and continuing physical cause
has been found in terms of tissue damage, illness or
otherwise, that requires treatment, such as pain due to
cancer or recent post traumatic pain, are excluded from
the study and advised to seek such treatment. Other
exclusion criteria are:
*a PHQ-9 < 10 or a BPI score < 3,
*alcohol use >3 units (1 unit = 1 glass of ≥0.25 l) a day
or drug abuse or dependence in the last 6 months,
defined as current use of any hard drugs (defined by
Dutch law, e.g. XTC, cocaine, heroine, magic
mushrooms) or cannabis, as evident from history or,
in case of suspicion during clinical interview, from
laboratory findings;
*psychotic symptoms or use of antipsychotic
medication that may influence perception of pain;
*use of St John’s wort (Hypericum Perforatum),
*pregnancy and breastfeeding,
*inability to participate in case of too severe language
barrier,
*dementia
*history of renal and liver dysfunction for which
treatment is needed
*uncontrolled hypertension despite treatment for
hypertension
*Lastly, suicidal ideation is an exclusion criterion if this
constitutes immediate danger and the need for crisis
management according to the consulted psychiatrist.This will be measured with the suicidal ideation item of
the PHQ-9. For this purpose, a suicide protocol is used in
the study, defining degrees of suicide risk and prescribing
necessary steps to be taken to advert such risk.
Exclusion of the study during the intervention phase
Non-compliance is defined as not having used at least
80% of the prescribed medication (duloxetine/placebo)
or no show on more than 20% of the appointments
made with the psychiatrist or care-manager. The psy-
chiatrist uses pill counts at every session to check if at
least 80% of the pills have been used.
Intervention
First and second design arm: Duloxetine/placebo plus
collaborative care This intervention contains collabora-
tive care, duloxetine or placebo, and pain medication
according to an algorithm. Collaborative care will be
provided within a multidisciplinary team comprising of a
care-manager, psychiatrist and a physiotherapist. They
all will apply treatment simultaneously according to
protocol. Only patients in the collaborative care arms
will receive treatment of all three specialists. The pa-
tients in the Duloxetine alone arm will only receive
treatment of the psychiatrist.
The GP of the patient will be informed of the partici-
pating of the patient. Also, GP's in the same areas as the
mental health centers will receive information about the
study and are asked to refer patients if they have the
complaints under study. The interventions will be moni-
tored every two weeks and when needed, the doses of
medication can be raised according to the algorithm
shown in Figures 2 and 3. The minimum duration of the
interventions will be 12 weeks. The medication blinding
code will be broken after 12 weeks. A maximum of 2
sessions will follow to end the treatment. After this,
medication and follow up treatment will be handed over
to the GP. In case of treatment response (50% reduction
on the initial score), but non-remission, as indicated by
a score of > 5 on the PHQ-9 after 12 weeks, the patient
will be referred back to the GP with subsequent anti-
depressant treatment and pain medication advice.
The detailed content of the collaborative care interven-
tion is described below:
1. Diagnostic assessment of the nature of pain
symptoms
The nature and the extent of the pain symptoms will
be explored by the psychiatrist with the BPI and the
painDETECT [74]. The 'average pain' item from the BPI
will be used to assess the severity of the pain symptoms.
To identify the pain symptoms as nociceptive and/or
Use painDETECTScore 12Nociceptive pain
Score > 12 and < 19
Follow both trails
Score 19
Neuropatic pain
STEP1:Acetaminophen 3dd1000mg
STEP 2: Etoricoxib 1dd60 mg
When patient is >70 years of age OR 
cardiovascular charged, SKIP this step
STEP 3: Tramadol retard 1dd50-200 mg
STEP 1: Pregabaline 1dd75 mg
STEP 2: 2 weeks after STEP 1, increase
Pregabaline to 2dd75 mg
STEP 3: 2 weeks after STEP 2, increase
Pregabaline to 3dd75 mg
Algorithm for nociceptive pain Algorithm for neuropatic pain
STEP 4: 2 weeks after STAP 3, increase
Pregabaline to 2dd150 mg
STEP 5: When Pregabaline, 2 weeks after 
STEP 4, has no effect:
STOP!
and continue this algorithm
After 2 weeks:
painDETECT decreased 
with 3 points?
YES NO
After 2 weeks:
painDETECT decreased 
with 3 points?
After 2 weeks:
painDETECT decreased 
with 3 points?
After 2 weeks:
painDETECT decreased 
with 3 points?
YES
YES
YES
NO
NO
NO
Has the score 
decreased to 5-12 in
the past 2 sessions? If
so, add Etoricoxib 
1dd60mg to 
Pregabaline
Has the score 
decreased to 5-12 in
the past 2 sessions? If
so, add Etoricoxib 
1dd60mg to 
Pregabaline
Has the score 
decreased to 5-12 in
the past 2 sessions? If
so, add Etoricoxib 
1dd60mg to 
Pregabaline
Has the score 
decreased to 5-12 in
the past 2 sessions? If
so, add Etoricoxib 
1dd60mg to 
Pregabaline
After 2 weeks:
painDETECT decreased 
with 3 points?
YES NO
Next step as addition
After 2 weeks:
painDETECT decreased 
with 3 points?
YES NO
Is the score on the painDETECT stayed 
the same or has it increased?
Stayed the 
same
Increased
Next step as addition
Switch to STEP 1 of the 
neuropatic pain algorithm
Continue with STEP 2 of
the algorithm of 
nociceptive pain 
(Etoricoxib 1dd60mg)
Figure 2 Algorithm for pain medication. The left side shows the algorithm for medication when the patient has nociceptive pain. The right
side shows the algorithm for medication when the patient has neuropathic pain. In case of mixed pain, a switch can be done as indicated.
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patient can have both neuropathic pain and nociceptive
pain at the same time, our pain medication protocol has
been edited accordingly. Chronic pain may be a function
of a chronic underlying pathology that appears within 4
to 6 weeks of an initial trauma; however, in accordance
with the use of the terms chronic and subchronic pain
in musculoskeletal pain or back pain, we apply the terms
chronic and subchronic as follows: We define sub-
chronic pain as pain with at least 6 weeks and less
than 12 weeks duration, and chronic pain as pain of ≥
12 weeks duration [6].
2. Contracting
During the initial visit, the care-manager informs the pa-
tient about the depressive disorder and pain symptoms, and
their association. The treatment plan is then jointly formu-
lated by the psychiatrist, the care-manager and the patient.
3. Pain medication protocol
In this study, pain is divided in nociceptive pain and
neuropathic pain and treatment of pain will be appliedbased on which of these two sorts of pain a patient has.
Classification as nociceptive pain, neuropathic pain or
mixed pain will be done with the PainDETECT question-
naire that was specifically validated for this purpose [74].
In all instances, patients are urged to take the medica-
tion at preset intervals, in order to medicate properly so
as to prevent serious pain. In all instances, duloxetine
(or placebo) is prescribed as adjuvant.
The psychiatrist will use the painDETECT question-
naire to identify the pain as nociceptive or neuropathic.
When it is not clear in which of these two categories the
pain belongs, both the algorithms for nociceptive and
for neuropathic pain are followed. The algorithm for
nociceptive pain, is adapted and changed from the
WHO pain ladder [80]. It is updated for the use of
selective Coxinhibitors, the role of so-called adjuvants is
more prominent here; the role of opioids is much less
prominent, but the principle of adding medication that
is common in the WHO pain ladder, is maintained. This
algorithm has been developed by the research group and
was tested for feasibility in patients with mental disorder
in a prepilot of this trial.
Figure 2 shows a graphical version of above mentioned
algorithm.
STEP1: First 2 weeks Duloxetine/
placebo 1dd30 mg
STEP 2: 2 weeks after STEP 1
Duloxetine/placebo 1dd60 mg
Has the PHQ-9 score
decreased with 5 points OR is
the total score 5 or lower?
Use PHQ-9 for baseline score
NO
NO
STEP 3: Duloxetine/placebo 1dd90
mg
STEP 4:12 weeks after session 1:
Has the score of de PHQ
decreased with 50% in
comparison with session 1?
YES NO
Has the PHQ-9 score decreased
with 5 points OR is the total score
5 or lower?
Dose stays 1dd90mg!
Did the patient receive
duloxetine of placebo?
Duloxetine Placebo
Continue current dose
for 6 months,then the
phase out period can
start
Placebo can be
stopped.
Did the patient receive
duloxetine of placebo?
Duloxetine Placebo
STEP 5: Amitriptyline retard
1dd50 mg, titrate through
1dd100 mg to 1dd 150 mg.
Phase out duloxetine and
cross with Amitriptyline
according to STEP 5
Begin at STEP 1 of
this algorithm, but now
with duloxetine
YES
YES
Figure 3 Algorithm for antidepressant medication.
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GP, the GP is advised, through a Consultation Letter, to
continue the medication for a duration of 6 months, as is
advised in the 'NHG standard – depression' [81], a guide-
line for general practitioners. The GP will monitor pain
symptoms with the BPI during a consult, every 6 weeks.
4. Manual guided self-help for behavioral techniques
aimed at improving coping with pain
During the treatment, the patient works through a
self-help manual, guided by the care-manager. The man-
ual is based on several existing self-help books [43-46].This self-help book contains information about depres-
sion and pain symptoms and their interaction, anti-
depressant medication, relaxation techniques and a
diary for pain complaints. Every chapter contains exer-
cises for the patients to perform. The care-manager in-
forms the patient about the content of the manual,
reinforces achievements and motivates the patient to
continue. In the present study, the self-help manual is
part of a complete intervention package and is therefore
meant as additional to the other components of the
intervention.
5. Problem Solving Treatment
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psychological intervention, guided by the care-manager,
that has been shown to be effective in the management
of depressive disorders and stress related disorders [82].
The problem-solving approach consists of 7 stages and
is based on the common observation that emotional
symptoms are often associated with problems in daily
life and it encourages patients to formulate practical
ways of dealing with such problems. The goal of PST is
to teach patients to use their own skills and resources to
function better [82,83], thus improving coping skills.
6. Antidepressant medication
In the two collaborative care conditions, patients will
either receive duloxetine or placebo in a double blind
fashion. The psychiatrist will monitor medication use
according to protocol. In case of any adverse effects, an
adverse effects protocol is followed. The pharmacists
checks for possible interactions of the antidepressant
medication with other medication use of the pa-
tient and instructs the doctors providing treatment
accordingly.
Patients will start with a dose of 30 mg once daily in
the first two weeks and 60 mg once daily from the third
week. From this point the PHQ-9 will be used to mea-
sure the severity of depressive symptoms. Based on the
score on the PHQ-9, the dose will be raised (when the
score did not decrease; with a maximum of 90 mg) or
stay the same (when the score on the PHQ-9 has
decreased with 5 or more points or the score on the
PHQ-9 is 5 or lower). This use of the PHQ9 for moni-
toring was used as well in other collaborative care
studies in the Netherlands, with a focus on depression
[84-87]. By using the PHQ9, comparisons can also be
made with these studies. After 12 weeks the rando-
mization code will be broken and medication will be
prescribed if necessary in a standard continuation phase
of at least six months. Pharmacotherapy will be grad-
ually discontinued according to protocol and/or clini-
cians judgment. When the patient is referred back to the
GP, the GP is advised, through a Consultation Letter, to
continue duloxetine for the duration of 6 months. After
this period, if possible, the GP reduces and stops the use
of duloxetine in a period of 4 weeks. In case of placebo,
the GP is advised to only prescribe medication when the
patient still has depressive symptoms. Figure 3 shows the
graphical version of the abovementioned algorithm.
7. Monitoring treatment outcome and motivational
techniques aimed at improving adherence
Patient adherence will be improved by contracting and
psycho-education and by frequent follow-up appointmentsin which both adherence and progress will be evaluated.
Provider adherence will be improved by instructions from
the researchers. Treatment outcome is monitored with a
variety of questionnaires (see section 'Outcome parameters').
8. Referral to the physiotherapist by the care-manager
according to a protocol
Next to manual guided self-help, Problem Solving
Treatment and medication, patients receive physiother-
apy. The physiotherapist will treat patients according to
the protocol of 'graded activity'. This treatment consists
of information of physical and psychological processes
and how these can be intertwined. The next step is to
formulate reasonable goals on what to achieve with this
therapy. According to these goals, intermediate steps are
formulated that have to take into account the amount of
time that is predetermined.
The physiotherapist stimulates the patients with posi-
tive feedback. Also, the therapist works on a structured
time schedule to optimize the course towards the deter-
mined goals. Next to the exercises, the therapist pays at-
tention to the progress of the patients. This will be
illustrated by graphs and when positive, these serve as a
possible positive reinforcer and can motivate the patient.
The patients also conducts the exercises at home, so
these exercises generalize to situations the patients live in.
In this, the patients are stimulated by their physiotherapist.
9. Consultation Letter
The consultation letter is written by the psychiatrist
and is meant for the GP and the patient. In this letter,
the symptoms of the patient are described (somatic and
psychological). This letter will also contain the treatment
the patient has received in this study, as well as if the
patient improved or not. The expected course of the
complaints will be described, and with this an advice is
given how to continue treatment of the patient by the
GP. An advice is given for continuing medication (anti-
depressants and pain medication), the number of regu-
larly scheduled consults with the patient every 6 weeks
as checkup, to perform only physical examination if the
patient presents the same symptoms again, and refrain
from repeated lab or diagnostic procedures as well as to
avoid hospitalization, as long as the patient does not
deteriorate or presents with new symptoms. Also, the
GP can consult the psychiatrist if needed. This consult-
ation letter is sent 3 months after start of treatment,
when the patient is referred back to the GP.
Third design arm: duloxetine alone
In the Duloxetine alone condition, patients will receive
duloxetine according to the algorithm as described on
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nents, i.e. PST, manual guided self-help, pain medication,
physiotherapy, and a consultation letter, of collaborative
care will be given here. Patients in this condition will only
be prescribed Duloxetine by a psychiatrist.
Data collection
Measurement will take place at baseline (T0), and three,
six, nine and twelve months after baseline, respectively
T1, T2, T3 and T4.
Outcome parameters
1. Primary outcome measure
Primary outcome parameter
Primary parameter used to substantiate the study hy-
pothesis will be severity of depression (PHQ-9) [13]. The
severity of depressive symptoms is measured with the
Patient Health Questionnaire depression sub-scale [13],
a brief but validated instrument that scores each of the
DSM-IV criteria for major depressive disorder. Response
is defined as a 50% reduction in symptoms [13,39,88].
Remission is defined as < 5 points on the PHQ-9 [88].
2. Secondary outcome measure
Secondary parameters
Secondary parameter will be the severity of pain symp-
toms as measured with the total BPI. The BPI has
been validated for chronic non-malignant pain [79].
The localization of pain and pain being nociceptive,
neuropathic or mixed of nature is assessed at the be-
ginning of the treatment by use of the PAINDETECT
questionnaire [74].
In addition to the improvement in the severity of symp-
toms, the cost utility of the three conditions will be com-
pared to each other. To evaluate the cost utility of each
condition, the difference in direct medical costs per pa-
tient receiving collaborative care and duloxetine, collab-
orative care and placebo, or Duloxetine alone is related to
the difference in terms of Quality Adjusted Life Years
(QALY) gained. This will yield a cost per QALY estimate.
These data will be collected with the Trimbos/iMTA ques-
tionnaire for Costs associated with Psychiatric Illness
(TiC-P), a measure commonly applied in economic evalu-
ations of treatment in mental care [89,90]. The TiC-P
measures direct costs of medical treatment such as the
number of contacts with the general practitioner and mul-
tiple other care providers (e.g. paramedics and medical
specialists) during the last three months. Medication use
is measured during the last four weeks. Also, the TiC-P in-
cludes a short form of the Health and Labor questionnaire
(HLQ) for collecting data on productivity losses [91], theSF-HLQ. It measures productivity loss by collecting data
on absence from work, reduced efficiency at work and dif-
ficulties with job performance [92].
The EuroQoL (EQ-5D) [93] and the Short Form-36
(SF-36) [94] will be used to assess quality of life. Both are
validated instruments for the measurement of general
health-related quality of life. The EQ-5D measures quality
of life on five dimensions, namely mobility, self-care, usual
activities, pain/discomfort and anxiety depression.
3. Additional outcome measures
Confusion exists in terminology in describing physical
symptoms and pain associated with depression [5,95]: They
may be somatised symptoms of MDD, or so-called asso-
ciated symptoms [96]; Medically Unexplained Symptoms,
that frequently occur together with MDD [97]; chronic
painful physical conditions that are symptoms of a chronic
illness, such as diabetic neuropathy; or chronic painful
conditions resulting from centralisation of a formerly
peripheral pain symptom [63]. In this study, we use the
psychiatrist's professional view on whether what kind of
physical symptoms a patient has. Comorbid mental disor-
ders will be assessed with the PHQ and GAD7 [98]. Hypo-
chondriac tendencies will be measured using the Whitely
Index [99]. The Patient-Doctor relationship Questionnaire
(PDRQ-9) [100] will be used to measure the patient doctor
relationship from the perspective of the patient. Physical
symptoms are measured by the Physical Symptoms Ques-
tionnaire (LKV: Lichamelijke Klachten Vragenlijst) [101].
The Morisky Medication Adherence Scale (MMAS) [102]
will be used to measure pain medication adherence. The
questionnaire TiC-P (‘vragenlijst voor zorggebruik en pro-
ductieverliezen bij psychische aandoeningen') [89] will be
used to assess provided health care. To measure coping in
stressful situations, the 'Coping Inventory for Stressful
Situations (CISS) [103], Dutch version, will be used. To
measure the tendency to overload, the 'Tendency to
Overload Questionnaire' (TOQ) short form will be used
[in press].
4. Controlling variables
The following demographic variables are measured at
baseline and will be taken into account as possible effect
modifiers: age, gender, nationality and ethnicity, marital
status, living conditions, education and work status.
Also, pain classification (neuropathic, nociceptive, sub-
chronic, chronic) will be taken as effect modifier. More-
over, existing somatic comorbidity will be taken as effect
modifier. Co-morbid chronic medical illness will be
measured with the Dutch Central Bureau for Statistics
list (CBS list). The list contains 28 chronic conditions
(e.g. diabetes and MS).
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Sample size for severity of depression as primary outcome
In a former RCT on collaborative care performed in the
primary care setting, the effect size of a collaborative care
intervention versus no such intervention as measured by
PHQ-9 was 4.64/7.6 = 0.6 (the SD on the endpoint PHQ-9
varied between 7.0 and 8.3) [104]. In this study, we com-
pare collaborative care plus duloxetine and collaborative
care plus placebo versus the monotherapy duloxetine
alone, and we compare collaborative care plus duloxetine
versus collaborative care plus placebo. To have a minimum
power of 80% to detect a standardized difference of 0.5 a
minimum of 63 patients per arm is needed, that is 189
completers. In order to anticipate for possible loss to follow
up of 20%, 3 × 79 (237) patients will be included [105].
Analysis
Apart from patients that will have to be excluded because
of noncompliance as described above, or patients who had
to undergo emergency deblinding due to serious medical
adverse events, intention to treat analysis will be
performed. Multi Level Analysis will be performed which
will allow us to correct for variance associated with the
different sites in this Multisite RCT. Effect sizes will be es-
timated in terms of Cohen's d and regression analysis will
be performed. Possible confounders such as age, gender,
immigrant status, level of education, history of treatment
and life events will be included as covariates in the ana-
lysis. An independent Helmert analysis will be performed
with the following contrasts: Duloxetine alone versus
TCCCL + duloxetine and TCCCL + placebo; and then
TCCCL + duloxetine versus TCCCL plus placebo.
To assess the cost effectiveness, we will apply a cost-
utility analysis. The results will be expressed as cost per
QALY. The economic evaluation will be undertaken
from a societal perspective. Hence, all relevant effects
and costs due to resource utilisation within the
healthcare (direct medical costs) and costs due to pro-
duction losses (productivity costs) will be included.
Controlling variables in analysis
As possible effect modifiers, co morbid mental health
disorders as measured with the PHQ (e.g. anxiety) will be
taken into account. Another parameter will be the severity
of hypochondriac tendencies (WI) as a possible effect
modifier [99]. The CBS list ‘chronic diseases’, developed by
the Dutch Central Bureau of Statistics, will be used to
evaluate physical co morbidity that may cause pain (e.g.
Diabetes, Multiple Sclerosis). Process measures will be
compliance and adherence to treatment, measured by the
self-report questionnaire Morisky Medication Adherence
Scale (MMAS) [102] and the patient-doctor relationship
as measured by the PDRQ-9 [100], as well as assessmentof the care provided in both conditions [89]; this includes
care the patients have received up to a year before they fill
in the baseline questionnaire.
Timeframe of the study
The goal is to enroll 219 patients in order to obtain 189
patients that will complete the study. The preparatory
period is approximately 6 months. Care-managers will
be recruited subsequent to the approval of the Medical
Ethical Board and the care-managers will be trained.
The inclusion and intervention period will be 24 months.
The follow-up phase will last 12 months. Data analysis
will take 6 months. The entire study period is 4 years.
Ethical principles
This study will be conducted in accordance with the
code of ethics that has been established by the decla-
ration of Helsinki (1964) and amended in Edinburgh
(2000). Subjects will be informed of all procedures and
asked for written informed consent. The patients will be
informed that they can withdraw their consent to
participate at any time without specification of reasons
and without negative consequences with regard to future
medical treatment. A medical adverse events protocol is
established. Every session with the psychiatrist side-effects,
that may have occurred since the last session, will be mea-
sured with the Dutch translation of the Antidepressant
Side-Effects Checklist (ASEC-21) [106]. When the patient
has a serious side-effect not mentioned on the ASEC-21,
an adverse medical events protocol will be followed,
involving emergency deblinding.
The study has been approved by the Medical Ethics
Committee of the VU Medical Centre (reference number:
08072).
Dissemination of results
This study will establish cost effectiveness of TCCCL
and then make the following products available for long
term implementation:
– Training module of psychiatrists and psychiatric
nurses working in a specialty mental health outpatient
clinic to perform TCCCL integrated depression and
pain treatment, and to refer the patient back to the
GP with a CL letter within 3 months.
– Format of a Consultation Letter to the GP.
– Algorithm for psychiatrists about how to monitor
and improve the pain medication of the patient
according to a protocol.
– A manual for the psychiatric nurses to monitor
progress and to use the DVD ‘Facts on Depression’
in psycho education for the patient.
– A self management manual for patients including
activation and relaxation techniques.
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Discussion
This paper describes the study protocol of a Multi-
Center randomized controlled trial evaluating collabora-
tive care, antidepressant medication and pain medication
in the treatment of depressive disorders with (sub)
chronic pain. The aim of this study is to compare three
treatments in terms of (cost)effectiveness.
A strength of this study is that the three arm design
enables us to show the value of a closely monitored
integrated treatment model above usual pharmacological
treatment. Another strength of the study is that the
comparison with a placebo arm enables us to evaluate
effectiveness of duloxetine in this population in a real
life setting.
Also, a strong aspect of this design is that this will
provide evidence-based treatments and tools for their
implementation in practice. This will facilitate generaliza-
tion and implementation of results of this study.
Furthermore, patients included in this study are
screened for pain symptoms, differentiating between
nociceptive and neuropathic pain, unlike the studies of
Goldstein et al. [107]. Therefore, pain relief can be tho-
roughly evaluated.
Another strength of the study is the structured imple-
mentation of a transmural model, aimed at better collab-
oration between GP and specialty mental health clinic in
complex patients with depression and concomitant (sub)
chronic pain.
A limitation of the study is that, with this study design,
we will not be able to make inferences about the effect-
iveness of the respective ingredients of the collaborative
care model (such as PST or the self-help manual).
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